Home/Filings/4/0001099219-24-000270
4//SEC Filing

DEBEL MARLENE 4

Accession 0001099219-24-000270

CIK 0001099219other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:20 PM ET

Size

12.0 KB

Accession

0001099219-24-000270

Insider Transaction Report

Form 4
Period: 2024-12-13
DEBEL MARLENE
EVP & Chief Risk Officer
Transactions
  • Exercise/Conversion

    Employee Stock Options (right to buy)

    2024-12-1313,1070 total
    Exercise: $34.33Exp: 2026-02-22Common Stock (13,107 underlying)
  • Sale

    Common Stock

    2024-12-13$82.88/sh22,810$1,890,577108,507 total
  • Exercise/Conversion

    Common Stock

    2024-12-13$34.33/sh+13,107$449,963121,614 total
  • Exercise/Conversion

    Employee Stock Options (right to buy)

    2024-12-139,7030 total
    Exercise: $45.91Exp: 2025-02-23Common Stock (9,703 underlying)
  • Exercise/Conversion

    Common Stock

    2024-12-13$45.91/sh+9,703$445,465131,317 total
Footnotes (3)
  • [F1]The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $82.83 to $82.931, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
  • [F2]The options became exercisable in three substantially equal installments on February 23, 2017, 2018, and 2019.
  • [F3]The options became exercisable in three substantially equal installments on February 24, 2016, February 24, 2017, and February 27, 2018.

Issuer

METLIFE INC

CIK 0001099219

Entity typeother

Related Parties

1
  • filerCIK 0001770295

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:20 PM ET
Size
12.0 KB